Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

Original reporting
Published Nov 9, 2026, 9:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial — source image
Decision brief

The 30-second read

$LSTABullishMed
01

Why it matters

The data represent a material clinical milestone that could de‑risk the program and attract partnership or financing opportunities.

02

Market read

Positive trial results are likely to drive short‑term buying interest in LSTA and may influence the broader lipid‑therapy sector.

03

What to watch

Regulatory pathway uncertainty and competition from other triglyceride‑lowering agents.

Relevance 8/10Novelty 8/10Timing: today

Background

Lisata Therapeutics (NASDAQ:LSTA) announced Phase 2b data for its experimental antibody MAR001, targeting ANGPTL4, showing up to 72.2% triglyceride reduction in severe hypertriglyceridemia patients.

Company-level read

Ticker impact

$LSTABullishHigh confidence
Context

Lisata Therapeutics subsidiary Marea Therapeutics reported up to 72% triglyceride reduction in a Phase 2b trial, a first‑time disclosure of pivotal data.

Expected impact

likely upward pressure as investors price in the positive trial outcome

Evidence & confidence

Data exceed expectations, meet primary endpoints, and suggest a viable first‑in‑class therapy, prompting buy‑side interest.

Market effects

May boost sentiment for lipid‑metabolism biotech peers and raise interest in ANGPTL4‑targeted therapies.

Limited to US biotech sector; no broader regional effect.

Potentially relevant to global investors tracking novel cardiovascular treatments.

Counterpoint

If Phase 3 fails to replicate efficacy or safety, the current hype could reverse sharply.

Key entities

  • Lisata Therapeutics Inc

    US‑listed biotech developing MAR001.

  • Marea Therapeutics

    Lisata's subsidiary conducting the trial.

Related articles

$LSTAMedAI 8/10

Marea Therapeutics doses first patient in MAR002 phase 2 trial

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

$LSTALow

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

$LSTAHighAI 8/10

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.